IT WAS WITH a growing sense of apprehension that I read the letter sent in June from the U.S. Senate finance committee to pharmaceutical companies asking them to explain their process for awarding educational grants. The senators want to make sure that grants to healthcare organizations are not a guise for promotion and influence-peddling. They said they were gathering information to see if further guidance or legislation (gulp) is needed. (See news story, page 15.) In the list of questions ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock the Choose Change, you'll also gain access to exclusive premium content.

Already registered? here.